Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma
Abstract Background Abnormal autocrine fibroblast growth factor 19 (FGF19) production has been observed in several types of cancers, including hepatocellular carcinoma (HCC). In this study, we investigated the potential of serum FGF19 as a novel tumor marker of HCC based on a sandwich enzyme-linked...
Main Authors: | Takahiro Maeda, Hiroaki Kanzaki, Tetsuhiro Chiba, Junjie Ao, Kengo Kanayama, Susumu Maruta, Yuko Kusakabe, Tomoko Saito, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Sadahisa Ogasawara, Eiichiro Suzuki, Yoshihiko Ooka, Shingo Nakamoto, Ryo Nakagawa, Ryosuke Muroyama, Tatsuo Kanda, Hitoshi Maruyama, Naoya Kato |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-11-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-019-6322-9 |
Similar Items
-
Switching to systemic therapy after locoregional treatment failure: Definition and best timing
by: Sadahisa Ogasawara, et al.
Published: (2020-04-01) -
The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma
by: Hiroaki Kanzaki, et al.
Published: (2021-03-01) -
Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials
by: Keisuke Koroki, et al.
Published: (2020-07-01) -
EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma
by: Yuko Kusakabe, et al.
Published: (2021-11-01) -
Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma.
by: Sadahisa Ogasawara, et al.
Published: (2016-01-01)